Docetaxel and Ramucirumab as Subsequent Treatment After First-Line Immunotherapy-Based Treatment for Metastatic Non-Small-Cell Lung Cancer: A Retrospective Study and Literature Review
<b>Background</b>: A combination of docetaxel and ramucirumab represents a standard of care in second-line treatment for patients with advanced NSCLC. Evidence of the regimen’s efficacy is based on the results of the REVEL trial conducted in the pre-immunotherapy (immune checkpoint inhibitors–ICIs)...
Spremljeno u:
| Glavni autori: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2025-11-01
|
| Serija: | Current Oncology |
| Teme: | |
| Online pristup: | https://www.mdpi.com/1718-7729/32/11/612 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|